REMS a cross departmental challenge for drugmakers says PPD

By Gareth Macdonald

- Last updated on GMT

Related tags Management Pharmaceutical drug

REMS a cross departmental challenge for drugmakers says PPD
The US FDA’s risk evaluation mitigation strategy (REMS) can be a challenge for pharmaceutical companies unfamiliar with the process according to PPD’s executive director of risk management Frank Gallo.

Gallo told Outsourcing pharma that, while they allow drugs that would otherwise not reach the market to do so, REMS require the development of an effective strategy and considerable inter-departmental collaboration for successful implementation.

He went on to explain that one of the biggest hurdles pharmaceutical firms face is deciding how medical, legal and commercial departments will collaborate as all are stakeholders in REMS development.

Beyond this, Gallo continued, designing the REMS so that it meets both patient safety and commercial goals is a significant undertaking.

Related news

Related products

Small Molecule development – getting it right

Small Molecule development – getting it right

Content provided by Lonza Small Molecules | 20-Jun-2023 | Insight Guide

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can...

The Complete Guide to eRegulatory and eSource

The Complete Guide to eRegulatory and eSource

Content provided by Florence Healthcare | 01-Apr-2023 | Insight Guide

Shifting to eRegulatory and eSource workflows is a requirement for clinical trial sites to continue to scale and grow their studies. This guide is designed...